After a case of durable response to IL-13Rα2- targeting CAR-T in relapsed multifocal GBM was reported in 2009 [211], a Phase 1 clinical trial was performed to evaluate safety and tolerability of a CAR-T product against IL-13Rα2 in recurrent high grade glioma, the majority of which was GBM. The gene discussed is IL13RA2; the disease is central nervous system cancer.